PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-08-30
DOI
10.1002/ijc.31770
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- (2016) Benjamin H. Lok et al. CLINICAL CANCER RESEARCH
- World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015
- (2016) Shelley McGuire Advances in Nutrition
- mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer
- (2015) W. Mo et al. CLINICAL CANCER RESEARCH
- The JNK Signaling Pathway Is a Novel Molecular Target for S-Propargyl- L-Cysteine, a Naturally-Occurring Garlic Derivatives: Link to Its Anticancer Activity in Pancreatic Cancer In Vitro and In Vivo
- (2015) Wei Wang et al. CURRENT CANCER DRUG TARGETS
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Regulators of homologous recombination repair as novel targets for cancer treatment
- (2015) Małgorzata Krajewska et al. Frontiers in Genetics
- Hyperthermia Inhibits Recombination Repair of Gemcitabine-Stalled Replication Forks
- (2014) Mustafa Raoof et al. JNCI-Journal of the National Cancer Institute
- Genome-wide transcriptome profiling of homologous recombination DNA repair
- (2014) Guang Peng et al. Nature Communications
- Chemotherapy induced DNA damage response
- (2013) Derek Woods et al. CANCER BIOLOGY & THERAPY
- Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
- (2013) R. J. Cardnell et al. CLINICAL CANCER RESEARCH
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- Topoisomerase I poisoning results in PARP-mediated replication fork reversal
- (2012) Arnab Ray Chaudhuri et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
- (2011) Neil Johnson et al. NATURE MEDICINE
- Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
- (2010) K. Hastak et al. CANCER RESEARCH
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- PARP inhibition in BRCA-mutated breast and ovarian cancers
- (2010) Stephen L Chan et al. LANCET
- PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
- (2009) Helen E Bryant et al. EMBO JOURNAL
- PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases
- (2009) Andreína Peralta-Leal et al. FREE RADICAL BIOLOGY AND MEDICINE
- The DNA-damage response in human biology and disease
- (2009) Stephen P. Jackson et al. NATURE
- The cancer genome
- (2009) Michael R. Stratton et al. NATURE
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started